EPCIS 1.2 vs 2.0: What Changes in Practice



EPCIS 1.2 vs 2.0: What Changes in Practice

Published on 01/12/2025

EPCIS 1.2 vs 2.0: What Changes in Practice

As the pharmaceutical industry continually adapts to evolving regulations and technologies, the Electronic Product Code Information Services (EPCIS) plays a transformative role in maintaining the integrity of supply chains. The transition from EPCIS 1.2 to 2.0 introduces significant changes that influence various aspects of serialization, aggregation, and the management of master data governance. This guide provides a detailed, step-by-step understanding of the changes in practice, especially concerning User Requirement Specifications (URS), interface validation, and the implications for regulatory compliance in the US, UK, and EU.

Understanding EPCIS and Its Relevance

The EPCIS standard enables visibility across the pharmaceutical supply chain by allowing trading partners to share >event-based data concerning the movement and status of products. As the global market faces stricter compliance requirements, particularly with the Drug Supply Chain Security Act (DSCSA) in the U.S. and the EU Falsified Medicines Directive (FMD), the adoption of EPCIS 2.0 is paramount for effective serialization and aggregation programs.

Key Features of EPCIS 1.2

  • Event Reporting: Provides a basic framework for reporting product events.
  • Data Structure: Utilizes XML-based formatting which allows limited scalability.
  • Serialization and Aggregation: Covers metadata aspects but lacks detailed specifications on hierarchical data definitions.

With these foundational aspects, companies have been able to achieve a degree of compliance, but the industry demands a more flexible and comprehensive solution as we transition into EPCIS 2.0.

Transitioning from EPCIS 1.2 to 2.0

The release of EPCIS 2.0 comes equipped with significant advancements aimed at enhancing the efficiency of supply chain operations. For professionals involved in serialization URS and interface validation, understanding the impact of these changes is crucial.

Enhanced Data Model

One of the major modifications from 1.2 to 2.0 is the introduction of an enhanced data model that expands the definitions of serialized products. This comes with new capabilities for representing complex product hierarchies with clear aggregation rules, a necessary advancement for robust master data flows.

  • Aggregation Hierarchy: The ability to represent various product packaging levels—cases, pallets, and units—enables clearer order visibility and alignment with regulatory audit trails.
  • Master Data Governance: An improved schema supports better data integrity practices aligned with ALCOA+ principles.

Revised Reconciliation and Exception Handling

The reconciliation rules have been more rigorously defined in EPCIS 2.0, enabling organizations to maintain data integrity effectively. The changes necessitate a comprehensive understanding of exception handling protocols that relate to discrepancies in product movement and data mismatches.

  • Audit Trail Review: A more robust audit trail signifies the generation of automatic logs that document every transaction, thus facilitating easier compliance with regulations such as those imposed by the European Medicines Agency (EMA).
  • CAPA Requirements: Enhanced requirements for Corrective and Preventive Actions tied to serialization discrepancies ensure thorough investigations and resolution mechanisms.

Developing User Requirement Specifications (URS)

Creating a detailed URS is essential for the effective implementation of EPCIS 2.0. The URS should detail all expectations related to functionality, data integrity, and compliance with both regional regulations and the overarching EPCIS specifications.

Elements of a Comprehensive URS

  • Functional Requirements: Clearly outline how each aspect of EPCIS 2.0 will interact with existing systems.
  • Performance Metrics: Identify specific metrics for validation success, including reconciliation goals and exception handling response times.
  • Regulatory Compliance: Ensure that all specifications align with local regulations, including DSCSA and EU FMD requirements.

Collaboration Across Teams

It is imperative that teams across pharmaceutical operations, regulatory affairs, and quality assurance collaborate during the URS development process. This collaboration ensures that all necessary input is captured, and that the validation process considers the entirety of the product lifecycle.

Interface Validation for EPCIS 2.0

As organizations implement EPCIS 2.0, interface validation becomes a critical aspect to ensure that all systems can seamlessly communicate and share data. This step is vital in maintaining integrity and compliance within the supply chain.

Establishing Validated Interfaces

To validate interfaces, operations should follow a systematic approach, ensuring that integration points are thoroughly tested against the URS:

  • Functional Testing: Each system should be tested to verify that it adheres to predefined functional requirements as specified in the URS.
  • Data Integrity Checks: Ensure that data transferred between systems adheres to ALCOA+ principles—data should be attributable, legible, contemporaneous, original, and accurate.
  • Exception Management Systems: Testing should include how systems manage exceptions to ensure compliance is maintained even when discrepancies arise.

Documentation and Training

Documentation of the validation process is crucial for readiness during audits. Furthermore, training programs must be established to ensure that relevant staff are proficient in using the new systems and understand the implications of EPCIS 2.0 on their work processes.

Implementing Serialization Change Control

With any new serialized product introduction under EPCIS 2.0, proper change control must be implemented. Serialization change control encompasses procedures aimed at managing any alterations in the product serialization process.

Change Control Steps

  • Impact Assessment: Evaluate how changes may affect existing supply chain integrity and compliance.
  • Approval Process: Incorporate a clear approval process that includes cross-departmental reviews focusing on risk assessment.
  • Training Updates: Develop training sessions to inform staff of any changes in procedures or systems affected by serialization updates.

Maintaining Compliance

The implementation of serialization change control, aligning with regulatory guidance such as PIC/S and FDA expectations, establishes a foundation for compliance continuity throughout the supply chain. Thorough documentation and audit readiness will sustain regulatory conformity and fortify stakeholder confidence in product integrity.

Conclusion

The transition from EPCIS 1.2 to 2.0 represents a significant advancement for the pharmaceutical industry, emphasizing enhanced data management, robust reconciliation protocols, and stricter compliance measures. Implementing these changes necessitates careful consideration of URS, validation procedures, and serialization control measures to ensure alignment with established regulations such as the DSCSA and EU FMD.

As pharmaceutical professionals navigate these changes, collaboration, thorough documentation, and continuous training will be instrumental in achieving compliance and operational excellence. Understanding and executing the outlined steps will help organizations adapt effectively to the evolving demands of the regulatory landscape and maintain high standards of product integrity.